(Q35695439)

9 August 2017

1 reference

title

Clinical interest of PPARs ligands (English)

1 reference

9 August 2017

Vergès B

1

1 reference

9 August 2017

publication date

1 February 2004

1 reference

9 August 2017

published in

Diabetes and Metabolism

1 reference

9 August 2017

volume

30

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

7-12

1 reference

Peroxisome proliferator-activated receptors: nuclear control of metabolism

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970083-6

7 January 2021

10.1016/S1262-3636(07)70083-6

Identifiers

DOI

1 reference

9 August 2017

1 reference